The BioPharm Brief: Bispecifics, Biocatalysis, and Dual-Pathway Therapies

Why It Matters

The announcements signal deeper pipelines for next‑generation immunotherapies, more cost‑effective peptide production, and a promising therapeutic strategy for patients who have exhausted existing IBD options, potentially reshaping market dynamics in oncology, cardiovascular, and gastro‑intestinal sectors.

Key Takeaways

• Harbour BioMed launches first-in-human bispecific trial for solid tumors
• Merck unveils enzyme-driven scalable process for oral peptide drugs
• Johnson & Johnson shows dual‑pathway IBD therapy improves remission
• B7H4 target expands bispecific pipeline beyond HER2 and CD3
• Oral PCSK9 inhibitor could disrupt injectable cholesterol market

Pulse Analysis

Bispecific antibodies are rapidly moving from niche concepts to mainstream oncology candidates. Harbour BioMed’s HBM7004 targets the B7H4 checkpoint, a less‑explored antigen that may complement existing CD3‑engaging platforms such as blinatumomab. By physically linking T cells to tumor cells expressing B7H4, the therapy aims to boost localized cytotoxicity while limiting systemic cytokine release, a balance that could improve safety profiles and broaden indications beyond hematologic cancers.

Manufacturing has long been a bottleneck for oral peptide therapeutics, especially macrocyclic formats that struggle with low yields and complex purification. Merck’s biocatalytic approach leverages engineered enzymes to assemble enlicitide decanoate, followed by crystallization‑based purification that sidesteps costly chromatography steps. This method not only lowers production costs but also accelerates scale‑up, positioning oral PCSK9 inhibition as a viable competitor to injectable monoclonal antibodies and potentially opening the door for other peptide‑based drugs targeting metabolic and rare diseases.

In inflammatory bowel disease, the dual‑pathway strategy embodied by JNJ‑4804 reflects a shift toward simultaneous modulation of multiple cytokine axes. By co‑targeting IL‑23 and TNF‑α, Johnson & Johnson addresses the redundancy that often undermines single‑target biologics, delivering higher remission and endoscopic response rates in patients with refractory ulcerative colitis and Crohn’s disease. If later‑stage trials confirm these findings, the co‑antibody could capture a sizable share of the $15 billion IBD market and inspire similar multi‑target designs across autoimmune therapeutics.